Renaissance Technologies
ARTV

Renaissance Technologies’s Artiva Biotherapeutics ARTV Stock Holding History

Renaissance Technologies’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$515K Sell
80,038
-36,162
-31% -$179K ﹤0.01% 2589
2025
Q4 		$498K Buy
116,200
+37,053
+47% +$140K ﹤0.01% 2578
2025
Q3 		$227K Buy
+79,147
New +$212K ﹤0.01% 3100

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Renaissance Technologies's ARTV Position: Q1 2026 in Review

Renaissance Technologies reduced its Artiva Biotherapeutics (ARTV) stake by 31% in Q1 2026, selling an estimated $179K and leaving 80,038 shares worth $515K. The position accounts for ﹤0.01% of the portfolio, ranked #2589.

Renaissance Technologies first reported a position in ARTV in Q3 2025 and has held it in 3 quarters since. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Renaissance Technologies held 80,038 shares of Artiva Biotherapeutics worth $515K as of Q1 2026.
  • Renaissance Technologies sold 36,162 Artiva Biotherapeutics shares in Q1 2026, an estimated $179K.
  • Artiva Biotherapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2589 holding.
  • Renaissance Technologies first reported a position in Artiva Biotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.